Viloxazine plasma concentrations and clinical response

Area of Science:

• Pharmacology
• Psychiatry
• Clinical Trials

Background:

• Primary depressive illness is a significant mental health concern.
• Viloxazine is an antidepressant medication.
• Understanding the relationship between drug concentration and efficacy is crucial for treatment optimization.

Purpose of the Study:

• To investigate the relationship between plasma viloxazine concentrations and treatment outcomes in patients with primary depressive illness.
• To assess if plasma viloxazine levels correlate with the severity of depression and patient response.
• To determine if side effects are associated with viloxazine plasma concentrations.

Main Methods:

• Eleven patients with primary depressive illness received 300 mg/d of viloxazine for 29 days.
• Weekly blood samples were collected to measure plasma viloxazine levels.
• Depression severity was assessed using the Hamilton depression rating scale.
• Correlation analyses were performed between plasma concentrations and depression scores.

Main Results:

• Mean plasma viloxazine level was 1.20 micrograms/ml (range: 0.40-2.70 micrograms/ml).
• No significant correlation was observed between plasma viloxazine concentration and depression amelioration scores at days 8, 22, or 29.
• No significant difference in plasma concentrations was found between responders and non-responders on day 29.
• Side effects were not correlated with plasma viloxazine concentrations.

Conclusions:

• Plasma viloxazine concentration does not appear to be a reliable predictor of antidepressant efficacy or side effects in patients with primary depressive illness.
• Further research may be needed to explore other factors influencing viloxazine's effectiveness.
• The findings suggest that therapeutic drug monitoring of viloxazine may not be necessary for this patient population.